<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531502</url>
  </required_header>
  <id_info>
    <org_study_id>IMPRESS</org_study_id>
    <nct_id>NCT03531502</nct_id>
  </id_info>
  <brief_title>Initial Management of Patients Receiving a Single Shock (IMPRESS)</brief_title>
  <acronym>IMPRESS</acronym>
  <official_title>Initial Management of Patients Receiving a Single Shock (IMPRESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjaya Gupta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Luke's Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the optimal treatment for patients who receive a
      single shock from their implantable cardioverter defibrillator (ICD). All participants in
      this study will be fitted with a special electrode vest to detect the origin of heart rhythm
      abnormalities and then they will undergo a procedure called Non-Invasive Programmed
      Stimulation (NIPS). This procedure involves sedating a participants with anesthesia and then
      using the participant's own ICD to try to stimulate the heart to go into ventricular
      tachycardia. If this procedure is unable to induce the participant into ventricular
      tachycardia, then the participant will just be managed with usual care and will not be placed
      on any additional medications and will not undergo an ablation. However, if the NIPS induces
      the ventricular tachycardia, the electrode vest will be used to determine the origin of the
      abnormal heart rhythm inside the heart. After a successful NIPS procedure, the participants
      will be randomly assigned to either be placed on medication therapy or undergo catheter
      ablation. The outcomes from all three groups will be compared and the researchers hope to
      better understand which participants are most likely to benefit from watchful waiting versus
      medication versus catheter ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a history of ventricular tachycardia requiring defibrillation or who are at
      risk for developing ventricular tachycardia will undergo placement of an implantable
      cardioverter defibrillator (ICD) for purposes of prevention of sudden cardiac arrest. While
      the ICD is lifesaving, if a patient receives a shock from their ICD it is painful and the
      entire experience is very traumatic. Traditionally, the management of these patients who
      receive a single shock from their ICD is variable because it is not known if the patient will
      continue to experience further shocks or not. Some physicians will initiate antiarrhythmic
      medical therapy after only a single shock, whereas others will wait until the patient has
      recurrent ICD shocks before initiating therapy. All patients should be counseled to not drive
      for 6 months following a shock. Ventricular tachycardia ablation, a procedure involving
      placing catheters from the groin into the chambers of the heart to isolate the source of
      ventricular tachycardia and eliminate these foci through delivery of radiofrequency energy,
      is typically reserved for patients with multiple recurrent cases of ventricular tachycardia.
      While some studies have shown that ventricular tachycardia ablations can be done safely at an
      earlier course of the disease and this procedure has been demonstrated to reduce further ICD
      shocks, this practice is not commonplace.

      Patients who undergo a ventricular tachycardia ablation procedure, will initially have
      catheters placed into the ventricular chambers of the heart and these catheters will be used
      to stimulate the heart in an attempt to induce the ventricular tachycardia, a process known
      as programmed stimulation. One major limitation of a ventricular tachycardia ablation
      procedure is the need to be able to induce the ventricular tachycardia rhythm via programmed
      stimulation. If this rhythm cannot be induced then it is very difficult to perform the
      ventricular tachycardia ablation procedure. Non-invasive programmed stimulation (NIPS) is a
      means of performing programmed stimulation using the patient's own ICD and does not involve
      placing catheters into the heart.

      Aim: The aim of this study is to investigate if non-invasive programmed stimulation (NIPS)
      can be used to risk stratify patients determine if earlier intervention with either
      antiarrhythmic medications or ablation in patients with recurrent ventricular tachycardia
      that received ICD shocks would help decrease further ICD shocks and hospitalizations for
      ventricular arrhythmias.

      Primary hypothesis: Patients receiving a single ICD shock for ventricular tachycardia who
      undergo a non-invasive programmed stimulation (NIPS) that fails to induce any sustained
      ventricular tachycardia, are at low likelihood of experiencing recurrent ICD shocks within
      the next year.

      Secondary hypothesis: For patients receiving a single ICD shock for ventricular tachycardia
      who undergo non-invasive programmed stimulation (NIPS) that induces a sustained, monomorphic
      ventricular tachycardia rhythm, the performance of ventricular tachycardia ablation will
      reduce the incidence of recurrent ICD shocks within the next year, as compared to
      antiarrhythmic therapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICD Shocks</measure>
    <time_frame>12 months</time_frame>
    <description>Number of recurrent ICD shocks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Number of related deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>Number of related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ATP Therapy as recorded by ICD</measure>
    <time_frame>12 months</time_frame>
    <description>Number of ATP therapies administered by ICD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-sustained VT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of antiarrythmic medication</measure>
    <time_frame>12 months</time_frame>
    <description>Number of times new medical therapy was started as documented in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of antiarrythmic medication</measure>
    <time_frame>12 months</time_frame>
    <description>Number of times medical therapy was changed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of repeat ablation procedures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Standard medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have a positive NIPS study and are randomized to the medical therapy arm will either be initiated on antiarrhythmic therapy or will have their antiarrhythmic therapy intensified. All medication therapy is considered usual standard therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventricular Tachycardia Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have a positive NIPS study and are randomized to the ablation arm will undergo ventricular tachycardia ablation procedure guided by CardioInsight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative NIPS/Non-intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who had a negative NIPS study will not be assigned to a treatment group and will be followed according to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ventricular Tachycardia Ablation</intervention_name>
    <description>Ventricular Tachycardia Ablation</description>
    <arm_group_label>Ventricular Tachycardia Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Therapy</intervention_name>
    <description>For the antiarrhythmic na√Øve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.</description>
    <arm_group_label>Standard medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-Invasive Programmed Stimulation (NIPS)</intervention_name>
    <description>All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.</description>
    <arm_group_label>Standard medical therapy</arm_group_label>
    <arm_group_label>Ventricular Tachycardia Ablation</arm_group_label>
    <arm_group_label>Negative NIPS/Non-intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old, both males and females

          -  Single or dual chamber ICD or BiVentricular ICD in situ

          -  Ischemic or non-ischemic cardiomyopathy

          -  Receive a single shock from their ICD for monomorphic ventricular tachycardia

        Exclusion Criteria:

          -  ICD shock for polymorphic VT/VF or inappropriate shock

          -  Previous ventricular tachycardia ablation within 1 year

          -  NYHA Class IV heart failure or current inotrope therapy

          -  Ventricular tachycardia storm

          -  Listed for heart transplant or LVAD

          -  Pregnant as determined by urine pregnancy test prior to NIPS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjaya Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Luke's Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Rutherford, RN, BSN</last_name>
    <phone>816-932-3147</phone>
    <email>cjrutherford@saint-lukes.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Rutherford, RN, BSN</last_name>
      <phone>816-932-3147</phone>
      <email>cjrutherford@saint-lukes.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007 Dec 27;357(26):2657-65.</citation>
    <PMID>18160685</PMID>
  </results_reference>
  <results_reference>
    <citation>Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016 Jul 14;375(2):111-21. doi: 10.1056/NEJMoa1513614. Epub 2016 May 5.</citation>
    <PMID>27149033</PMID>
  </results_reference>
  <results_reference>
    <citation>Frankel DS, Mountantonakis SE, Zado ES, Anter E, Bala R, Cooper JM, Deo R, Dixit S, Epstein AE, Garcia FC, Gerstenfeld EP, Hutchinson MD, Lin D, Patel VV, Riley MP, Robinson MR, Tzou WS, Verdino RJ, Callans DJ, Marchlinski FE. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol. 2012 Apr 24;59(17):1529-35. doi: 10.1016/j.jacc.2012.01.026.</citation>
    <PMID>22516442</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Saint Luke's Health System</investigator_affiliation>
    <investigator_full_name>Sanjaya Gupta</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, University of Missouri-Kansas City</investigator_title>
  </responsible_party>
  <keyword>tachycardia</keyword>
  <keyword>defibrillator</keyword>
  <keyword>arrythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

